Abstract
Ghrelin is a gastric hormone that stimulates growth hormone (GH) secretion and food intake to regulate energy homeostasis and body weight by binding to its receptor, GH secretagogue receptor (GHSR1a), which is most highly expressed in the pituitary and hypothalamus. Nowadays there is considerable evidence showing that the GHSR1a is also expressed in numerous extra-hypothalamic neuronal populations and the physiological role of ghrelin is by far wider than considered before including learning and memory, anxiety, depression and neuroprotection. The present review attempts to provide a comprehensive picture of the role of ghrelin in the central nervous system and to highlight recent findings showing its potential as an innovative therapeutic agent in neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
Keywords: Ghrelin, neuroprotection, Alzheimer’s disease, Parkinson’s disease, learning and memory, anxiety, depression
Current Pharmaceutical Design
Title:Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Volume: 19 Issue: 38
Author(s): Vanessa V. dos Santos, Ana Lúcia S. Rodrigues, Thereza C. De Lima, Susana R. de Barioglio, Rita Raisman-Vozari and Rui D. Prediger
Affiliation:
Keywords: Ghrelin, neuroprotection, Alzheimer’s disease, Parkinson’s disease, learning and memory, anxiety, depression
Abstract: Ghrelin is a gastric hormone that stimulates growth hormone (GH) secretion and food intake to regulate energy homeostasis and body weight by binding to its receptor, GH secretagogue receptor (GHSR1a), which is most highly expressed in the pituitary and hypothalamus. Nowadays there is considerable evidence showing that the GHSR1a is also expressed in numerous extra-hypothalamic neuronal populations and the physiological role of ghrelin is by far wider than considered before including learning and memory, anxiety, depression and neuroprotection. The present review attempts to provide a comprehensive picture of the role of ghrelin in the central nervous system and to highlight recent findings showing its potential as an innovative therapeutic agent in neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
Export Options
About this article
Cite this article as:
V. dos Santos Vanessa, S. Rodrigues Ana Lúcia, C. De Lima Thereza, R. de Barioglio Susana, Raisman-Vozari Rita and D. Prediger Rui, Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/13816128113199990411
DOI https://dx.doi.org/10.2174/13816128113199990411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Childhood and Adulthood Rural Residence Increases the Risk of Dementia: NEDICES Study
Current Alzheimer Research Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Clinical Observation of Liver Chemistry Abnormalities in Asthmatics
Current Drug Safety Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Mitral Stenosis in Pregnancy: A Comprehensive Review of a Challenging Cardio-Obstetric Clinical Entity
Reviews on Recent Clinical Trials Recent Advances in Ozonation of Vegetable Oils
Recent Patents on Materials Science New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Advances in Antithrombotic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design Nanomedicine Against Malaria
Current Medicinal Chemistry Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Monocyte Cyclooxygenase-2 Activity: A New Therapeutic Target for Atherosclerosis?
Current Drug Targets - Cardiovascular & Hematological Disorders Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Current Topics in Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome
Current Medicinal Chemistry Myths and Facts Concerning the Use of Statins in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets